-
-
Overview
-
Please contact us at for specific academic pricing.
Background
AMG-510 is an effective, orally bioavailable, selective KRAS G12C covalent inhibitor. AMG-510 locks KRAS G12C in an inactive GDP constraint. AMG-510 is the first KRAS G12C inhibitor to be clinically developed, which can cause KRAS G12C tumor regression.
-
- Properties
-
Overview